Our previous SPORE had separate Cores for tissue collection/curation (old Core A: National Tissue Resource) and for pathologic evaluation (old Core C: Pathology), but in this new application they are combined in one Core, the National Tissue Resource and Pathology Core (NTRPC), since they are highly integrated and work closely with one another. The NTRPC also collaborates closely with Core B (Biostatistics and Data Management), which is responsible for informatics to manage inventory and annotation data. The objectives of the NTPRC are: (1) To provide centralized support for acquisition, banking, management, and distribution of tissue within the SPORE, and to maintain and update the databases with annotation and follow-up associated with these tissues. We will manage and distribute tissue and data from legacy inventories to qualified researchers, inside and outside our SPORE;collect, quality control, manage, and distribute newly acquired breast cancer materials including clinical trial specimens to qualified researchers;and annotate materials already in the collections from appropriately consented subjects with additional clinical, pathologic and follow-up information. (2) To provide histologic assessment and quality control of these tissues, along with tissue-based studies such as IHC using these clinical specimens as well as mouse tissues from the preclinical experiments. We will quality control and perform accurate pathologic assessment of tumors;and coordinate and manage the pathology support for the SPORE projects, developing new assays as required and working with the investigators to determine the methodologies most appropriate for their needs. The NTRPC is a continuation of two existing, well-functioning, and absolutely essential Cores. Although the guidelines state that

Public Health Relevance

Lack access to high quality, well annotated clinical specimens is a major impediment to progress in translational research. Core A has a long-standing and exemplary track record for making such tissues available to investigators inside and outside the SPORE. Further, breast cancer is a heterogeneous disease that requires trained histotechnologists, and very experienced pathologists to perform and interpret assays, and to properly handle valuable pre-clinical and highly annotated clinical specimens.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-C (M1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Baylor College of Medicine
United States
Zip Code
Zhao, Na; Cao, Jin; Xu, Longyong et al. (2018) Pharmacological targeting of MYC-regulated IRE1/XBP1 pathway suppresses MYC-driven breast cancer. J Clin Invest 128:1283-1299
Bhat, Raksha R; Yadav, Puja; Sahay, Debashish et al. (2018) GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancer. Breast Cancer Res Treat 170:279-292
Guarducci, Cristina; Bonechi, Martina; Benelli, Matteo et al. (2018) Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer. NPJ Breast Cancer 4:38
Johnston, A N; Bu, W; Hein, S et al. (2018) Hyperprolactinemia-inducing antipsychotics increase breast cancer risk by activating JAK-STAT5 in precancerous lesions. Breast Cancer Res 20:42
Dasgupta, Subhamoy; Rajapakshe, Kimal; Zhu, Bokai et al. (2018) Metabolic enzyme PFKFB4 activates transcriptional coactivator SRC-3 to drive breast cancer. Nature 556:249-254
Rimawi, Mothaffar F; De Angelis, Carmine; Contreras, Alejandro et al. (2018) Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer. Breast Cancer Res Treat 167:731-740
Bajgain, Pradip; Tawinwung, Supannikar; D'Elia, Lindsey et al. (2018) CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation. J Immunother Cancer 6:34
Niravath, Polly; Chen, Bingshu; Chapman, Judy-Anne W et al. (2018) Vitamin D Levels, Vitamin D Receptor Polymorphisms, and Inflammatory Cytokines in Aromatase Inhibitor-Induced Arthralgias: An Analysis of CCTG MA.27. Clin Breast Cancer 18:78-87
Hertz, D L; Kidwell, K M; Hilsenbeck, S G et al. (2017) CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study. Breast Cancer Res Treat 166:277-287
Yu, L; Liang, Y; Cao, X et al. (2017) Identification of MYST3 as a novel epigenetic activator of ER? frequently amplified in breast cancer. Oncogene 36:2910-2918

Showing the most recent 10 out of 28 publications